Drug Combination Details
| General Information of the Combination (ID: C05591) | |||||
|---|---|---|---|---|---|
| Name | Ellagic acid NP Info | + | Temozolomide Drug Info | ||
| Structure |
|
+ |
|
||
| Disease |
Brain cancer
[ICD-11: 2A00]
|
Investigative | [1] | ||
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. Enhancing Drug Efficacy by This Combination | ||||||
| Augmenting Drug Sensitivity | Click to Show/Hide | |||||
| Experiment 1 Reporting the Effect of This Combination | [1] | |||||
| Molecule(s)
Regulation |
Up-regulation | Expression | CDH1 | Molecule Info |
Pathway MAP
|
|
| Down-regulation | Expression | CDH2 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | VEGFA | Molecule Info |
Pathway MAP
|
||
| In-vitro Model | C6 | CVCL_0194 | Rat malignant glioma | Rattus norvegicus | ||
| Experimental
Result(s) |
Combining ellagic acid with temozolomide mediates the cadherin switch and angiogenesis in a glioblastoma model. | |||||
| References | ||||
|---|---|---|---|---|
| Reference 1 | Combining Ellagic Acid with Temozolomide Mediates the Cadherin Switch and Angiogenesis in a Glioblastoma Model. World Neurosurg. 2019 Dec;132:e178-e184. | |||
